adefovir dipivoxil + nelfinavir + saquinavir

**adefovir dipivoxil + nelfinavir + saquinavir** is a combination of three antiviral agents used in the treatment of HIV and potentially other viral infections. - **Adefovir dipivoxil** is a prodrug of adefovir, an acyclic nucleotide analog. It is phosphorylated intracellularly to adefovir diphosphate, which inhibits viral DNA polymerases by competing with deoxyadenosine triphosphate, causing DNA chain termination and thereby blocking replication of viral DNA. It is primarily active against hepatitis B virus (HBV), but also displays activity against HIV, herpes viruses, and other DNA viruses[1][3][5]. - **Nelfinavir** and **saquinavir** are protease inhibitors used in HIV therapy. Both act by inhibiting the HIV-1 protease enzyme, preventing viral maturation and the production of infectious virions. Nelfinavir is often used in combination regimens for antiretroviral therapy; saquinavir can be boosted with ritonavir or used in combination with other protease inhibitors. - Combination therapies using nelfinavir and saquinavir have been utilized for HIV, sometimes showing synergistic or additive antiviral effects, although pharmacokinetic interactions can be unpredictable[2][6]. This specific combination is not widely recognized as a uniquely named product, but rather as a regimen composed of the three agents for multi-drug antiretroviral therapy in HIV, where overlapping and complementary mechanisms of action enhance antiviral efficacy and help prevent resistance.